1471-0528/asset/BJO_left.gif?v=1&s=0fb87361cdb6be25fdf05019eed6d47f5143f610)
1471-0528/asset/olbannerright.gif?v=1&s=3892ef16ff18d6834c302faf85268a49f5fc588f)
The prognostic and therapeutic value of second-look laparotomy in advanced ovarian cancer
Article first published online: 19 AUG 2005
DOI: 10.1111/j.1471-0528.1988.tb06811.x
Issue
1471-0528/asset/cover.gif?v=1&s=b4e1d96c46e18c61210d584b63c13ee375cf562b "BJOG: An International Journal of Obstetrics & Gynaecology")
BJOG: An International Journal of Obstetrics & Gynaecology
Volume 95, Issue 12, pages 1231–1236, December 1988
Additional Information
How to Cite
BERTELSEN, K., HANSEN, M. K., PEDERSEN, P. H., LARSEN, G., NYLAND, M., JACOBSEN, M. and ANDERSEN, J. E. (1988), The prognostic and therapeutic value of second-look laparotomy in advanced ovarian cancer. BJOG: An International Journal of Obstetrics & Gynaecology, 95: 1231–1236. doi: 10.1111/j.1471-0528.1988.tb06811.x
Publication History
- Issue published online: 19 AUG 2005
- Article first published online: 19 AUG 2005
- Received 24 November 1987, Accepted 17 March 1988
- Abstract
- References
- Cited By
Summary. Of 267 patients with ovarian cancer FIGO stages III and IV, 157 underwent second-look laparotomy after combination chemotherapy consisting of cis-platinum and cyclophosphamide with and without doxorubicin. At second-look operation 45% had macroscopic tumour, 15% microscopic tumour, and 40% complete pathological response. Survival 3 years after second look was: complete pathological response 74%; microscopic disease 24%; visible tumour <1 cm 28%; visible tumour >1 cm 17%; negative cytology 59%; and positive cytology 18%. Of the patients with macroscopic tumour, 29% had all visible tumour removed at second look. Three-year survival for these patients was about 45%.